Juniper Pharmaceuticals Pharmaceutical company

Diplomat Pharmacy Inc. (DPLO) said Friday it was postponing the release of its fourth-quarter and full-year 2018 earnings as it and its auditors finalize the level of an impairment charge.

The company said its results and conference call have been pushed back to March 15. The company said it expects to file its 10-K for the fiscal year ended Dec. 31, 2018, soon after.

Results for January came in significantly below expectations -- that's just one of the reasons the company listed for also withdrawing the 2019 full-year outlook it provided less than a month ago. The company's outlook of 2018 revenue of $5.5 billion to $5.6 billion and 2018 adjusted EBITDA of $167 million to $170 million remains unchanged, as they are not impacted by the impairment charge, the pharmacy services company said in a release.

"The postponement is due primarily to the recent determination by Diplomat and its auditors that the company will need to record a non-cash impairment charge related to its PBM business. This charge is expected to be equal to a significant portion of the PBM's Goodwill and Definite-lived intangible assets, which total approximately $630 million as of December 31, 2018, prior to impairment charges. The charge relates to the 2017 acquisitions of NPS and LDI and is driven by reduced financial forecasts for the PBM business,"  the company said in a press release.

There are three buy ratings and eight hold ratings on the stock, according to Factset. The price target ranges from $14 to 24.

The stock was down 56.39% to $5.87 on Friday.